// Real-Time Intelligence Feed

Financial Intelligence.
Real-Time.

SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.

18,990
Stories Indexed
Live
Feed Status
6
Data Sources
AllEarningsFDAM&AInsider TradingRegulatoryOfferingLeadershipRestructuringDividendInstitutional HoldingsBankruptcy
ALL STORIES · 18,990 results Live
FDA ACTAVIS Jun 2 — 0.00

FDA Approves Unknown Drug — ACTAVIS LABS FL INC

Actavis Labs Florida, Inc. secured FDA approval for its generic sildenafil citrate tablets (20 mg), clearing the way for a competitive launch in the Pulmonary Arterial Hypertension…

FDA Cipla May 19 — 0.00

FDA Approves ATORVASTATIN CALCIUM — Cipla USA Inc.,

The FDA has approved a supplementary ANDA for oral atorvastatin calcium by Cipla USA Inc., allowing the company to expand its generic cholesterol-lowering offerings. This clearance…

FDA Genentech, May 18 — 0.00

FDA Approves TECENTRIQ — Genentech, Inc.

# FDA Approves Genentech's TECENTRIQ (atezolizumab) for Bladder Cancer Genentech, Inc. received FDA approval for TECENTRIQ (atezolizumab), a PD-L1 inhibitor administered intraveno…

FDA PHARMOBEDIENT Apr 28 — 0.00

FDA Approves Unknown Drug — PHARMOBEDIENT

Pharmobedient Continues Regulatory Expansion Pharmobedient has expanded its product portfolio with this latest FDA approval, positioning itself for broader market penetration withi…

FDA Aurolife Apr 26 — 0.00

FDA Approves OXYMORPHONE HYDROCHLORIDE — Aurolife Pharma, LLC

Aurolife Pharma, LLC announced the FDA approval of its OxyMORPHONE HYDROCHLORIDE tablets, increasing generic availability in the opioid market and facilitating price competition ag…

FDA Collegium Apr 26 — 0.00

FDA Approves XTAMPZA ER — Collegium Pharmaceutical, Inc.

Collegium Pharmaceutical, Inc. capitalized on the FDA's April 26, 2016 approval of its XTAMPZA ER extended-release opioid, positioning itself for significant revenue growth within …

FDA AMNEAL Apr 22 — 0.00

FDA Approves Unknown Drug — AMNEAL PHARMS

# FDA Approves Amneal Pharmaceuticals Generic Drug Application Amneal Pharmaceuticals received FDA approval for ANDA205081 on April 22, 2016, expanding its generic drug portfolio …

FDA Sandoz Apr 19 — 0.00

FDA Approves MEROPENEM — Sandoz Inc

# FDA Approves Sandoz's Generic Meropenem for Intravenous Use Sandoz Inc. has received FDA approval for its generic meropenem injection, expanding the competitive landscape in the…

FDA Amneal Apr 12 — 0.00

FDA Approves MORPHINE SULFATE — Amneal Pharmaceuticals of New York LLC

# FDA Approves Amneal Pharmaceuticals' Generic Morphine Sulfate Oral Formulation Amneal Pharmaceuticals of New York LLC received FDA approval for its generic morphine sulfate oral…

FDA AbbVie Apr 11 — 0.00

FDA Approves VENCLEXTA — AbbVie Inc.

# FDA Approves AbbVie's VENCLEXTA (venetoclax) for Chronic Lymphocytic Leukemia AbbVie Inc. received FDA approval for VENCLEXTA (venetoclax), an oral BCL-2 inhibitor for chronic l…

FDA Amneal Mar 17 — 0.00

FDA Approves DESIPRAMINE HYDROCHLORIDE — Amneal Pharmaceuticals NY LLC

# FDA Approves Desipramine Hydrochloride Generic Amneal Pharmaceuticals NY LLC has received FDA approval for its generic desipramine hydrochloride oral formulation, expanding trea…

FDA Pfizer Feb 23 — 0.00

FDA Approves XELJANZ XR — Pfizer Laboratories Div Pfizer Inc

On February 23, 2016, the FDA granted approval to Pfizer's oral TOFACITINIB CITRATE for XELJANZ XR, marking a strategic expansion of the rheumatoid arthritis market with a sustaine…

FDA ScieGen Feb 18 — 0.00

FDA Approves GABAPENTIN — ScieGen Pharmaceuticals, Inc.

# FDA Approves ScieGen Pharmaceuticals' Generic Gabapentin ScieGen Pharmaceuticals, Inc. received FDA approval for its generic gabapentin oral formulation, marking another entry i…

FDA Sagent Feb 17 — 0.00

FDA Approves FLUOROURACIL — Sagent Pharmaceuticals

# FDA Approves Sagent Pharmaceuticals' Generic Fluorouracil Injection Sagent Pharmaceuticals has received FDA approval for its generic fluorouracil intravenous formulation, expand…

FDA ACCORD Feb 5 — 0.00

FDA Approves Unknown Drug — ACCORD HLTHCARE

# FDA Approves ANDA Submission for Accord Healthcare Accord Healthcare has received FDA approval for its abbreviated new drug application (ANDA206058), expanding the company's gen…

FDA Creekwood Feb 4 — 0.00

FDA Approves GABAPENTIN — Creekwood Pharmaceuticals LLC

# FDA Approves Generic Gabapentin from Creekwood Pharmaceuticals Creekwood Pharmaceuticals LLC has received FDA approval for its generic gabapentin oral formulation, expanding the…

FDA Eugia Jan 14 — 0.00

FDA Approves TRANEXAMIC ACID — Eugia US LLC

Eugia US LLC received FDA approval for its ANDA for tranexamic acid intravenous injection (2016), a generic version of the marketed hemostatic agent. This clearance expands generic…

FDA Macleods Jan 11 — 0.00

FDA Approves LEVOCETIRIZINE DIHYDROCHLORIDE — Macleods Pharmaceuticals Limited

# FDA Approves Macleods Pharmaceuticals' Generic Levocetirizine Dihydrochloride Macleods Pharmaceuticals Limited received FDA approval for its generic levocetirizine dihydrochlori…

FDA Actelion Dec 21 — 0.00

FDA Approves UPTRAVI — Actelion Pharmaceuticals US, Inc.

# FDA Approves Actelion Pharmaceuticals' UPTRAVI for Pulmonary Arterial Hypertension Actelion Pharmaceuticals US, Inc. received FDA approval for UPTRAVI (selexipag), an oral medic…

FDA Lupin Dec 16 — 0.00

FDA Approves MORPHINE SULFATE — Lupin Pharmaceuticals,Inc.

Lupin Pharmaceuticals, Inc. announced that the FDA approved its Abbreviated New Drug Application (ANDA) for Morphine Sulfate Oral Solution, offering a cost-effective alternative fo…